This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

MP-EV20-DC54

MediaPharma S.r.l.

Drug Names(s): MPEV20DC54, MP EV20 DC54, EV20/DC-54

Description: EV20/DC-54 is a project aiming at developing an Antibody-Drug-Conjugate based on the humanized monoclonal antibody, EV20, recognizing HER-3 (human epidermal growth factor receptor 3, also known as ErbB-3) coupled to a Duocarmycin derivative.

Deal Structure: MediaPharma and Nerviano
In September 2016, MediaPharma and Nerviano Medical Sciences announced that they have signed a license and a supply agreement that will allow MediaPharma to develop Nervianos payload (drug-linker) technology on a MediaPharma-exclusive target for an ADC designed to meet unmet needs in the field of cancer.As a result of this agreement, Nerviano will receive undisclosed fees, development linked milestones and royalties for granting MediaPharma access to its technology. Nerviano will lead the effort in the manufacture and supply of its payload technology.

Partners: Nerviano Medical Sciences


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug